R&D
May 15, 2019
Sym021, a promising anti-PD1 clinical candidate antibody derived from a new chicken antibody discovery platform
MAbs. 2019 May 3:1-15. doi: 10.1080/19420862.2019.1596514
February 13, 2018
February 8, 2018
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses
JAMA Oncol. Published online February 8, 2018. doi:10.1001/jamaoncol.2017.5245
December, 2017
Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms.
Mol Cancer Ther. 2017 Dec;16(12):2780-2791
November 1, 2017
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression
J Natl Cancer Inst. 2017 Nov 1;109(11)
July 5, 2017
Sym015: A highly efficacious antibody mixture against MET amplified tumors
Clin Cancer Res. 2017 Jul 5. pii: clincanres.0782.2017. doi: 10.1158/1078-0432.CCR-17-0782. [Epub ahead of print]
PMID: 28679766 [PubMed - as supplied by publisher]
PMID: 28679766 [PubMed - as supplied by publisher]
September, 2016
Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab
Mol Cancer Ther. 2016 Sep;15(9):2175-86
July, 2016
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Clin Cancer Res. 2016 Jul 1;22(13):3260-7